Zoetis Inc. $ZTS Shares Sold by Penobscot Investment Management Company Inc.

Penobscot Investment Management Company Inc. lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 61.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,785 shares of the company’s stock after selling 6,034 shares during the period. Penobscot Investment Management Company Inc.’s holdings in Zoetis were worth $476,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC raised its stake in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the last quarter. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the 4th quarter worth $25,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the 3rd quarter worth $31,000. Finally, Holos Integrated Wealth LLC acquired a new position in shares of Zoetis during the 4th quarter worth $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several recent research reports. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Citigroup initiated coverage on Zoetis in a research report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price objective on the stock. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Piper Sandler restated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $152.25.

Zoetis Stock Down 0.6%

Shares of NYSE:ZTS opened at $117.46 on Thursday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 52-week low of $113.29 and a 52-week high of $172.23. The stock’s fifty day simple moving average is $121.21 and its 200-day simple moving average is $125.80. The company has a market capitalization of $49.41 billion, a P/E ratio of 19.51, a P/E/G ratio of 1.80 and a beta of 0.98.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the prior year, the business earned $1.40 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 7.02 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.